

IN THE CLAIMS

Please amend the claims as follows:

Claims 1-16 have been withdrawn

17. (Amended) A method of inhibiting angiogenesis in a diseased eye, comprising, administering intraocularly a retroviral gene delivery vector which directs the expression of an anti angiogenic factor, such that administration of said vector inhibits neovascularization of the diseased eye.

18. The methods according to claim 17 wherein said anti-angiogenic factor is soluble Flt-1, PEDF, soluble Tie-2 receptor, or, a single chain anti-VEGF antibody.

19. (Amended) The method according to claim 17 wherein said diseased eye is diabetic retinopathy, wet AMD and retinopathy of prematurity.

20. (Amended) The method according to claim 17 wherein said retroviral gene delivery vector is a retrovirus selected from the group consisting of HIV and FIV.

21. (Amended) The method according to claim 17 wherein said retroviral gene delivery vector is a recombinant adeno-associated viral vector.

B1 22. (Amended) A retroviral gene delivery vector which directs the expression of a neurotrophic factor, or an anti-angiogenic factor, whereby the administration of the retroviral gene delivery vector expressing the neurotrophic or anti-angiogenic factor into a diseased mammal inhibits neovascularization of the diseased tissue.

Claims 23-25 are withdrawn.

26. (Amended) The retroviral gene delivery vector according to claim 22 wherein said anti angiogenic factor is soluble Flt-1, PEDF, soluble tie-2 receptor, or, a single-chain anti-VEGF antibody.

27. (Amended) The retroviral gene delivery vector according to claim 22 wherein said vector is generated from a retrovirus selected from a group consisting of adeno-associated retroviruses and alpha viruses.

28. (Amended) The retroviral gene delivery vector according to claim 27 wherein the retrovirus is HIV or FIV.

29. Cancel

Claims 30-44 have been withdrawn.